Which weight-loss medication class should be avoided in patients with hypertension or heart disease?

Which weight-loss medication class should be avoided in patients with hypertension or heart disease?

• A. Sympathomimetics (phentermine/diethylpropion)
• B. Orlistat
• C. GLP-1 receptor agonists
• D. Lorcaserin

Answer: (A)

Stimulant weight-loss medications should be avoided in people with hypertension or heart disease because they stimulate the sympathetic nervous system, which raises blood pressure and heart rate. Drugs like phentermine and diethylpropion increase norepinephrine activity, leading to higher blood pressure, tachycardia, palpitations, and greater cardiac workload. In patients with already elevated cardiovascular risk, this can trigger hypertensive crises, worsen existing heart conditions, or precipitate arrhythmias, making these agents risky in HTN or heart disease. Orlistat works differently—it blocks fat absorption in the gut and has minimal systemic absorption, so it doesn’t meaningfully raise blood pressure or heart rate and is generally safer for those cardiovascular conditions. GLP-1 receptor agonists promote weight loss and often have neutral or even favorable cardiovascular effects, with some therapies showing reduced cardiovascular risk, so they’re not contraindicated in hypertension or heart disease. Lorcaserin acts on serotonin receptors to reduce appetite and doesn’t carry the same immediate stimulant effects on the heart and blood vessels, though it has its own safety considerations; it does not target cardiovascular risk in the same way stimulants do, so it isn’t the class to avoid specifically for hypertension or heart disease.

Stimulant weight-loss medications should be avoided in people with hypertension or heart disease because they stimulate the sympathetic nervous system, which raises blood pressure and heart rate. Drugs like phentermine and diethylpropion increase norepinephrine activity, leading to higher blood pressure, tachycardia, palpitations, and greater cardiac workload. In patients with already elevated cardiovascular risk, this can trigger hypertensive crises, worsen existing heart conditions, or precipitate arrhythmias, making these agents risky in HTN or heart disease.

Orlistat works differently—it blocks fat absorption in the gut and has minimal systemic absorption, so it doesn’t meaningfully raise blood pressure or heart rate and is generally safer for those cardiovascular conditions. GLP-1 receptor agonists promote weight loss and often have neutral or even favorable cardiovascular effects, with some therapies showing reduced cardiovascular risk, so they’re not contraindicated in hypertension or heart disease. Lorcaserin acts on serotonin receptors to reduce appetite and doesn’t carry the same immediate stimulant effects on the heart and blood vessels, though it has its own safety considerations; it does not target cardiovascular risk in the same way stimulants do, so it isn’t the class to avoid specifically for hypertension or heart disease.